Hologic (NASDAQ:HOLX) target raised to $44.00, reported today by Barclays
- Updated: September 23, 2016
Hologic (NASDAQ:HOLX) had its target bumped up to $44.00 by Barclays in a report released Friday September 23, 2016. The new stock price target implies a possible upside of 0.13% based on the company's most recent stock price.
Previously on 8/01/2016, RBC Capital Markets reported on Hologic (NASDAQ:HOLX) increased the target price from $37.00 to $39.00 that suggested a downside of 0.00%.
Showing a price of $38.78, Hologic (NASDAQ:HOLX) traded 0.46% higher on the day. The last close is up 8.58% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same time. The company has recorded a 50-day moving average of $38.36 and a 200-day moving average of $35.88. Volume of trade was down over the average, with 199,993 shares of HOLX changing hands under the typical 2,433,530
Recent Performance Chart
With a total market value of $0, Hologic has one year low of $31.84 and a one year high of $41.66 with a PE ratio of 42.95 .
A total of 16 brokers have issued a report on Hologic. 8 firms rating the company a strong buy, five firms rating the stock a buy, 8 firms rating the stock a hold, 0 brokers rating the stock a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $42.25.
Brief Synopsis About Hologic (NASDAQ:HOLX)
Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays. Its Breast Health products include a portfolio of breast imaging and related products and accessories, including digital mammography systems, computer-aided detection for mammography and minimally invasive breast biopsy devices, breast biopsy site markers and breast biopsy guidance systems. Its GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. Its Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.